Korean J Anesthesiol.  2008 Aug;55(2):217-220. 10.4097/kjae.2008.55.2.217.

Anesthesia for a 10-year-old boy with Duchenne muscular dystrophy syndrome: A case report

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Eulji University Hospital, College of Medicine, Eulji University, Daejeon, Korea. donghop6212@dreamwiz.com

Abstract

Duchenne muscular dystrophy (DMD) is an eventually fatal disorder that is characterized by rapidly progressive muscle weakness and atrophy of muscle tissue. The clinical manifestations of DMD vary depending on the stages of the disease. Succinylcholine-induced hyperkalemia and the administration of volatile anesthetic agents, - particularly halothane, - during acute rhabdomyolysis are more likely to result in cardiac arrest and unsuccessful resuscitation in DMD patients than in the general public. This is a case report of a 10-year-old boy who underwent elective strabismus revision under general anesthesia. Anesthesia was induced and maintained with intravenous propofol and remifentanil, which was started at the targeted effect concentration of 3.0micrometer/ml and 3.5 ng/ml respectively via target controlled infusion (TCI). No inhaled anesthetic was used. In addition, an initial dose 0.4 mg/kg of atracurium was injected intravenously over 15s. The results of this case report found intravenous infusion of propofol, remifentanil and atracurium to be safe because the malignant hyperthermia did not occur.

Keyword

cardiac arrest; DMD; rhabdomyolysis; TCI

MeSH Terms

Anesthesia
Anesthesia, General
Anesthetics
Atracurium
Atrophy
Child
Halothane
Heart Arrest
Humans
Hyperkalemia
Infusions, Intravenous
Malignant Hyperthermia
Muscle Weakness
Muscles
Muscular Dystrophy, Duchenne
Piperidines
Propofol
Resuscitation
Rhabdomyolysis
Strabismus
Anesthetics
Atracurium
Halothane
Piperidines
Propofol
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr